NSCLC-specific mortality not linked to beta-blockers

  • Udumyan R & al.
  • Cancer Epidemiol Biomarkers Prev
  • 22 Oct 2019

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Although beta-blocker use at the time of NSCLC diagnosis was not associated with lung cancer-specific mortality overall, there was a slight association between propranolol and increased lung cancer-specific mortality.

Why this matters

  • Previous studies had suggested a possible link between beta-blockers and a decreased risk for lung cancer-specific mortality.

Study design

  • 18,429 patients with NSCLC from the Swedish Cancer Register.
  • Funding: Swedish Cancer Society.

Key results

  • 28% were beta-blocker users, 45% of whom were high-dose users.
  • Metoprolol was the most common beta-blocker.
  • Most common indications for beta-blockers were hypertension (61%) and heart disease (59%).
  • Overall, there was no significant association between beta-blocker use and lung cancer-specific mortality, regardless of tumor stage or beta-blocker solubility or dose.
  • However, there was a slight association between propranolol and lung cancer-specific mortality (HR, 1.22; 95% CI, 1.03-1.45).
  • Similar results were found after propensity matching.

Limitations

  • Retrospective study.